Paradigm shift in activity assessment of IgA nephropathy - Optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting

Expert Opinion on Biological Therapy

Volumn 15, Issue 4, 2015, Pages 583-593

  Suzuki, Yusuke ^a   Suzuki, Hitoshi ^a   Yasutake, Junichi ^a,b   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nephrology RandD Unit   (Japan)

Author keywords

Anti glycan antibody; Biomarker; Disease activity assessment; Early diagnosis; Galactose deficient IgA1; Glycan engineering; IgA immune complex; IgA nephropathy

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANTIBODY; AUTOANTIBODY; GALACTOSE; GLYCAN; GLYCAN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; POLYSACCHARIDE;

ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; NON INVASIVE MEASUREMENT; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; PROTEINURIA; URINARY TRACT DISEASE ASSESSMENT; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; METABOLISM; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; GALACTOSE; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN A; IMMUNOLOGIC FACTORS; POLYSACCHARIDES;

EID: 84925280366     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1006624     Document Type: Article

References (71)

1. Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008;118:629-39
2. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011;22:1795-803
3. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013;368:2402-14
4. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000;36:227-37
5. Chauveau D, Droz D. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 1993;104:1-5
6. Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001;110:434-7
7. Shen P, He L, Li Y, et al. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract 2007;106:c157-61
8. Imai H, Miura N. A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission? Clin Exp Nephrol 2011;16:195-201
9. Sugiyama H, Yokoyama H, Sato H, et al. Japan renal biopsy registry and Japan kidney disease registry: committee report for 2009 and 2010. Clin Exp Nephrol 2013;17:155-73
10. Manno C, Strippoli GF, D'Altri C, et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kid Dis 2007;49:763-75
11. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007;71:159-66
12. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63:1468-74
13. Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res 2008;31:433-41
14. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-63
15. Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a doubleblind, randomized, placebo-controlled study. Am J Kidney Dis 2006;47:751-60
16. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines -- application to the individual patient. Kidney Int 2012;82:840-56
17. Japanese Society of Nephrology. Evidence-based Clinical Practice Guideline for CKD 2013. Clin Exp Nephrol 2014;18:346-423
18. Donadio JV, Grande JP. IgA Nephropathy. N Engl J Med 2002;347:738-48
19. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006;69:1455-8
20. Lee HS, Lee MS, Lee SM, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant 2005;20:342-8
21. Coppo R. Tonsillectomy as a treatment for IgA nephropathy: an old-fashioned story or still a feasible choice? NDT-EDUCATIONAL 2014. Available from: www.ndteducational. org/blog-253-15
22. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999;51:147-52
23. Piccoli A, Codognotto M, Tabbi MG, et al. Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol Dial Transplant 2010;25:2583-9
24. Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 2004;65:1135-44
25. Chen Y, Tang Z, Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol 2007;27:170-5
26. Maeda I, Hayashi T, Sato KK, et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant 2012;27:2806-13
27. Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 1980;66:1432-6
28. Mattu TS, Pleass RJ, Willis AC, et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fca receptor interactions. J Biol Chem 1998;273:2260-72
29. Renfrow MB, Cooper HJ, Tomana M, et al. Determination of aberrant Oglycosylation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem 2005;280:19136-45
30. Renfrow MB, Mackay CL, Chalmers MJ, et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry. Implications for IgA nephropathy. Anal Bioanal Chem 2007;389:1397-407
31. Takahashi K, Wall SB, Suzuki H, et al. Clustered O-glycans of IgA1. Defining macro- and micro-heterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics 2010;9:2545-57
32. Takahashi K, Smith AD, Poulsen K, et al. Identification of structural isomers in IgA1 hinge-region O-glycosylation using high-resolution mass spectrometry. J Proteome Res 2012;11:692-702
33. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995;100:470-4
34. Mestecky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993;104:172-82
35. Tomana M, Matousovic K, Julian BA, et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997;52:509-16
36. Moldoveanu Z, Wyatt RJ, Lee J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007;71:1148-54
37. Raska M, Moldoveanu Z, Suzuki H, et al. Identification and characterization of CMP-NeuAc:GalNAc-IgA1 a2,6- sialyltransferase in IgA1-producing cells. J Mol Biol 2007;369:69-78
38. Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008;19:1008-14
39. Suzuki H, Raska M, Yamada K, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc- II enzymes. J Biol Chem 2014;289:5330-9
40. Glassock RJ. The pathogenesis of IgA nephropathy. Curr Opin Nephrol Hypertens 2011;20:153-60
41. Yanagawa H, Suzuki H, Suzuki Y, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 2014;9:e98081
42. Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant Oglycosylation. Observations in three patients. Kidney Int 2001;60:969-73
43. Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001;59:1077-85
44. Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005;67:504-13
45. Suzuki H, Fun R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009;119:1668-77
46. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999;104:73-81
47. Novak J, Julian BA, Mestecky J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 2012;34:365-82
48. Camilla R, Suzuki H, Dapr-a V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 2011;6:1903-11
49. Gómez-Guerrero C, López-Armada MJ, Gonza'lez E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-a and IL-6, and proliferation. J Immunol 1994;153:5247-55
50. Tamouza H, Chemouny JM, Raskova Kafkova L, et al. IgA1 immune complex-mediated activation of MAPK/ ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int 2012;82:1284-96
51. Novak J, Raskova Kafkova L, Suzuki H, et al. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured mesangial cells. Nephrol Dial Transplant 2011;26:3451-7
52. Lai KN, Leung JC, Chan LY, et al. Activation of podocytes by mesangialderived TNF-a. Glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008;294:F945-55
53. Lai KN, Leung JC, Chan LY, et al. Podocyte injury induced by mesangialderived cytokines in IgA nephropathy. Nephrol Dial Transplant 2009;24:62-72
54. Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 2012;82:790-6
55. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactosedeficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;2:1579-87
56. Nakata J, Suzuki Y, Suzuki H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One 2014;9:e89707
57. Suzuki Y, Matsuzaki K, Suzuki H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol 2014;18:770-7
58. Shirato K, Nakajima K, Korekane H, et al. Hypoxic regulation of glycosylation via the N-acetylglucosamine cycle. J Clin Biochem Nutr 2011;48:20-5
59. Yoshizumi S, Suzuki S, Hirai M, et al. Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice. Metabolism 2007;56:420-9
60. Rudd PM, Elliott T, Cresswell P, et al. Glycosylation and the immune system. Science 2001;291:2370-6
61. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 2004;65:1544-7
62. Altmann F. The role of protein glycosylation in allergy. Int Arch Allergy Immunol 2006;142:99-115
63. Kato Y, Kaneko MK. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep 2014;4:1-9
64. Okuyama N, Ide Y, Nakano M, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803-8
65. Miyoshi E, Nakano M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008;8:3257-62
66. Laitinen L, Juusela H, Virtanen I. Binding of the blood group-reactive lectins to human adult kidney specimens. Anat Rec 1990;226:10-17
67. Franc V, Rehulka P, Raus M, et al. Elucidating heterogeneity of IgA1 hingeregion O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing. J Proteomics 2013;92:299-312
68. Sakai K, Shimizu Y, Chiba T, et al. Isolation and characterization of phagedisplayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies. Biochemistry 2007;46:253-62
69. Yuasa N, Zhang W, Goto T, et al. Production of anti-carbohydrate antibodies by phage display technologies: potential impairment of cell growth as a result of endogenous expression. J Biol Chem 2010;285:30587-97
70. Moore JS, Kulhavy R, Tomana M, et al. Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol 2007;44:2598-604
71. Suzuki Y, Suzuki H, Yasutake J. Serum galactose-deficient IgA1 detected by specific monoclonal antibody KM55 is increased in IgA nephropathy patients. American Society of Nephrology Annual Meeting. 2014. TH-PO372